Education
About Us
Working with TipRanks
Follow Us
CareDx (CDNA)
NASDAQ:CDNA
CDNA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.42 - $34.84
Previous CloseN/A
Volume177.07K
Average Volume (3M)790.78K
Market Cap
$1.02B
Enterprise Value$1.01B
Total Cash (Recent Filing)$114.69M
Total Debt (Recent Filing)$22.26M
Price to Earnings (P/E)18.0
Beta2.21
Next Earnings
May 01, 2025EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.02
Shares Outstanding55,425,900
10 Day Avg. Volume642,677
30 Day Avg. Volume790,777
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.21
Price to Cash Flow (P/CF)12.20
P/FCF Ratio12.20
Enterprise Value/Market Cap1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.04
Enterprise Value/Ebitda15.46
Forecast
1Y Price Target
$27.83Price Target Upside51.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
---
CareDx News
PremiumCompany Announcements
CareDx Inc. Reports Strong Growth and Positive Outlook
PremiumCompany Announcements
CareDx Reports Strong 2024 Financial Performance
PremiumCompany Announcements
CareDx Reports Strong 2024 Financial Results and Growth---
Bulls Say, Bears Say
Bulls Say
EarningsRevenue grew 30% YoY in 4Q24; $370M in revenue anticipated for 2025.
Financial PositionCDNA generated $22M of cash flow from operations in Q4 and holds $261M of cash, indicating a strong financial position.
Market PositionShares of CDNA are trading at a roughly 2-turn discount to its peers, suggesting the stock is undervalued given its strong market position and positive cash flow.
Bears Say
Investment RisksInvestment risks include failure of AlloMap and AlloSure tests to achieve commercial success due to market size, penetration rate, reimbursement and/or competition.
Net LossNet loss was between $32-34M for 4Q24 and between $58-60M for FY2024.
Stock PerformanceShares of CDNA have pulled back ~20% since its analyst day.
---
Ownership Overview
8.01% Insiders
25.14% Mutual Funds
0.08% Other Institutional Investors
44.37% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CDNA FAQ
What was CareDx’s price range in the past 12 months?
CareDx lowest stock price was $7.42 and its highest was $34.84 in the past 12 months.
What is CareDx’s market cap?
CareDx’s market cap is $1.02B.
When is CareDx’s upcoming earnings report date?
CareDx’s upcoming earnings report date is May 01, 2025 which is in 34 days.
How were CareDx’s earnings last quarter?
CareDx released its earnings results on Feb 26, 2025. The company reported $1.51 earnings per share for the quarter, beating the consensus estimate of -$0.408 by $1.918.
Is CareDx overvalued?
According to Wall Street analysts CareDx’s price is currently Undervalued.
Does CareDx pay dividends?
CareDx does not currently pay dividends.
What is CareDx’s EPS estimate?
CareDx’s EPS estimate is -0.21.
How many shares outstanding does CareDx have?
CareDx has 55,425,900 shares outstanding.
What happened to CareDx’s price movement after its last earnings report?
CareDx reported an EPS of $1.51 in its last earnings report, beating expectations of -$0.408. Following the earnings report the stock price went down -0.19%.
Which hedge fund is a major shareholder of CareDx?
Currently, no hedge funds are holding shares in CDNA
---
CareDx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$27.83 (51.66% Upside)
$27.83 (51.66% Upside)
Blogger Sentiment
Neutral
CDNA Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 759.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $367.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 11.7%
Last 30 Days ▼ 11.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
74.42%
12-Months-Change
Fundamentals
Return on Equity
19.46%
Trailing 12-Months
Asset Growth
4.30%
Trailing 12-Months
Company Description
CareDx
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
---
CDNA Company Deck
---
CDNA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment overall, with significant revenue growth, strong cash flow, and a notable legal victory. The company has successfully expanded its testing services and payer coverage. However, the guidance reflects caution due to possible seasonal impacts and a conservative ASP outlook.Read More>---
CDNA Stock 12 Month Forecast
Average Price Target
$27.83
▲(51.66% Upside)
Technical Analysis
Best Analysts Covering CDNA
1 Year
1 Year Success Rate
2/8 ratings generated profit
1 Year Average Return
-23.88%
reiterated a buy rating 5 months ago
Copying Matthew Sykes's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -23.88% per trade.
---